SNAP-8 (Acetyl Octapeptide-3)

Also known as: Acetyl octapeptide-3, Acetyl glutamyl heptapeptide-1

**Mechanism of Action** SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide designed as an extended analog of Argireline (Acetyl Hexapeptide-8). It competitively inhibits the assembly of the SNARE complex by mimicking the N-terminal domain of SNAP-25, a key protein in vesicle docking and neurotransmitter release. By displacing endogenous SNAP-25, the peptide reduces calcium-dependent exocytosis of acetylcholine at the neuromuscular junction, thereby attenuating muscle contraction. This mechanism is analogous to that of botulinum toxin but is reversible and non-toxic, targeting wrinkle formation through localized, temporary relaxation of facial muscles. **Key Research Findings** As an experimental compound, SNAP-8 has no published peer-reviewed studies indexed in PubMed (0 results). Available data are limited to in vitro assays and unpublished industry reports, which suggest enhanced stability and potency compared to Argireline due to its extended peptide chain. However, the absence of controlled clinical trials or pharmacokinetic evaluations precludes definitive conclusions regarding its efficacy, bioavailability, or long-term safety. Its classification as experimental underscores the need for rigorous investigation to validate claims of improved anti-wrinkle activity. **Clinical Relevance** SNAP-8 is primarily explored in cosmetic formulations as a topical anti-aging agent for dynamic wrinkles (e.g., crow’s feet, forehead lines). Its proposed advantage over Argireline lies in higher receptor affinity and prolonged action, potentially reducing application frequency. However, without clinical data, its translational value remains speculative. Regulatory status varies by region, and it is not approved for therapeutic use. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides